financetom
Business
financetom
/
Business
/
Hulu launches on Disney+ in bid to boost streaming use
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Hulu launches on Disney+ in bid to boost streaming use
Mar 27, 2024 6:31 AM

LOS ANGELES (Reuters) - Walt Disney ( DIS ) completed the addition of the general-audience-focused Hulu streaming service to the family friendly Disney+ on Wednesday, putting titles such as "The Bear" and "American Horror Story" in the same app as "Moana" and "Frozen."

The combination, which the company started testing last year, is designed to make viewing more convenient for customers and to increase Disney's ( DIS ) streaming subscriptions as cable TV usage declines.

Thousands of movies and TV shows from Hulu will be displayed alongside Disney ( DIS ) programming across the Disney+ app and in search results. Subscribers who do not yet pay for a Disney+ bundle will see prompts to add Hulu for an extra $2 per month.

Parental control settings will allow subscribers to restrict access to more mature content from Hulu in children's profiles, Disney ( DIS ) executives said.

Disney's ( DIS ) streaming TV unit has been losing money since Disney+ launched in November 2019. Chief Executive Bob Iger has said the business will turn a profit this year. The media giant is under pressure from activist investors who criticize the company for investing billions in its direct-to-consumer business but lagging behind industry-leader Netflix.

As of December 2023, Disney+ had nearly 150 million global subscribers and Hulu nearly 50 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing
Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing
Jun 7, 2024
04:07 PM EDT, 06/07/2024 (MT Newswires) -- Percy H. Carter, Chief Scientific Officer, on June 05, 2024, sold 4,000 shares in Blueprint Medicines ( BPMC ) for $420,520. Following the Form 4 filing with the SEC, Carter has control over a total of 41,895 shares of the company, with 41,895 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1597264/000141588924015943/xslF345X03/form4-06072024_040602.xml ...
Recursion Pharmaceuticals Insider Sold Shares Worth $871,000, According to a Recent SEC Filing
Recursion Pharmaceuticals Insider Sold Shares Worth $871,000, According to a Recent SEC Filing
Jun 7, 2024
04:07 PM EDT, 06/07/2024 (MT Newswires) -- Christopher Gibson, Director, Chief Executive Officer, on June 05, 2024, sold 100,000 shares in Recursion Pharmaceuticals ( RXRX ) for $871,000. Following the Form 4 filing with the SEC, Gibson has control over a total of 708,738 shares of the company, with 708,738 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000077/xslF345X03/wk-form4_1717790504.xml Price: 8.60, Change: +0.09,...
Cava Group Insider Sold Shares Worth $222,512,803, According to a Recent SEC Filing
Cava Group Insider Sold Shares Worth $222,512,803, According to a Recent SEC Filing
Jun 7, 2024
04:07 PM EDT, 06/07/2024 (MT Newswires) -- Ronald M Shaich, Director, on June 05, 2024, sold 2,550,290 shares in Cava Group ( CAVA ) for $222,512,803. Following the Form 4 filing with the SEC, Shaich has control over a total of 7,149,899 shares of the company, with 5,000 shares held directly and 7,144,899 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1639438/000162828024027251/xslF345X03/wk-form4_1717790405.xml Price: 85.00,...
Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing
Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing
Jun 7, 2024
04:06 PM EDT, 06/07/2024 (MT Newswires) -- Robert I Blum, Director, President & CEO, on June 04, 2024, sold 22,500 shares in Cytokinetics ( CYTK ) for $1,099,125. Following the Form 4 filing with the SEC, Blum has control over a total of 443,311 shares of the company, with 439,145 shares held directly and 4,166 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1061983/000112760224018143/xslF345X03/form4.xml...
Copyright 2023-2025 - www.financetom.com All Rights Reserved